Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Teosyal PureSense Redensity 1 is a non-crosslinked hyaluronic acid-based skinbooster developed by Teoxane. It is an injectable gel designed to improve skin quality by restoring hydration, increasing skin density, and enhancing radiance in areas such as the face, neck, décolleté, and hands. The formulation contains 15 mg/ml of non-crosslinked hyaluronic acid, 0.3% lidocaine hydrochloride for local anesthesia, and a proprietary Dermo-Restructuring Complex (DRC). The DRC includes 14 essential nutrients: eight amino acids (glycine, lysine, threonine, proline, isoleucine, leucine, valine, and arginine), three antioxidants (glutathione, N-acetyl-L-cysteine, and alpha-lipoic acid), two minerals (zinc and copper), and vitamin B6. The product works by physically replenishing the dermal matrix and providing essential nutrients to stimulate fibroblast activity, promoting the production of collagen and elastin while offering antioxidant protection against premature skin aging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Teosyal PureSense Redensity 1.